Capasso Nicola, Palladino Raffaele, Montella Emma, Pennino Francesca, Lanzillo Roberta, Carotenuto Antonio, Petracca Maria, Iodice Rosa, Iovino Aniello, Aruta Francesco, Pastore Viviana, Buonomo Antonio Riccardo, Zappulo Emanuela, Gentile Ivan, Triassi Maria, Brescia Morra Vincenzo, Moccia Marcello
Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy.
Department of Public Health, University of Naples "Federico II", 80138 Naples, Italy.
J Clin Med. 2020 Dec 16;9(12):4066. doi: 10.3390/jcm9124066.
We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates.
In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher's exact test, chi square test, or McNemar's test, as appropriate, to evaluate between-group differences.
We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) ( < 0.001), and similar to the low-risk population (n = 11, 1.3%) ( = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms.
MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.
我们比较了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫球蛋白G/免疫球蛋白M（IgG/IgM）在多发性硬化症（MS）患者、低风险人群和高风险人群中的流行情况，并探讨了可能的临床相关性。
在这项横断面研究中，我们于2020年5月11日至6月15日招募了MS患者、低风险人群（非临床科室的大学工作人员）和高风险人群（COVID-19病房的医护人员）。我们采用侧向流免疫分析法检测SARS-CoV-2 IgG和IgM。我们根据情况使用t检验、Fisher精确检验、卡方检验或McNemar检验来评估组间差异。
我们招募了310例MS患者（42.3±12.4岁；女性占67.1%）、862例低风险人群（42.9±13.3岁；女性占47.8%）和235例高风险人群（39.4±10.9岁；女性占54.5%）。MS患者中SARS-CoV-2 IgG/IgM的流行率（n = 9，2.9%）显著低于高风险人群（n = 25，10.6%）（P<0.001），与低风险人群（n = 11，1.3%）相似（P = 0.057）；在按年龄和性别进行1:1:1随机匹配后，这些结果也得到了证实。在人口统计学、临床、治疗和实验室特征方面未发现显著差异。在SARS-CoV-2 IgG/IgM呈阳性的MS患者（n = 9）中，只有两名患者回顾性报告有轻度且持续时间短的COVID-19症状。
MS患者感染SARS-CoV-2的风险与普通人群相似，即使使用全身免疫抑制治疗，也可能感染COVID-19但无症状。
